Načítá se...
High dose cytarabine, mitoxantrone, pegasapargase (HAM-pegA) in combination with dasatinib for the first-line treatment of Philadelphia chromosome positive mixed phenotype acute leukemia.
The treatment of mixed phenotype acute leukemia (MPAL) is challenging due to the presence of disease characteristics of both myeloid and lymphoid leukemia. Regimens historically used to treat acute lymphoblastic leukemia are often used to treat MPAL, particularly for patients whose diseases also pos...
Uloženo v:
| Vydáno v: | Am J Leuk Res |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2020
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7717491/ https://ncbi.nlm.nih.gov/pubmed/33283208 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|